6,7,4’-Trihydroxyisoflavone is an active metabolite of the phytoestrogen daidzein .^1,2,3,4 It suppresses anchorage-dependent and -independent growth of HCT116 and DLD-1 colon cancer cells, as well as induces cell cycle arrest at the S and G2/M phases in HCT116 cells when used at concentrations ranging from 12.5 to 100 µM.¹ 6,7,4'-Trihydroxyisoflavone (40 and 80 µM) inhibits adipogenesis in 3T3-L1 preadipocytes induced by isobutylmethylxanthine, dexamethasone, and insulin (MDI).² In vivo, 6,7,4'-trihydroxyisoflavone (5 mg/kg) reverses scopolamine-induced memory impairments and increases hippocampal brain-derived neurotrophic factor (BDNF) and CREB levels in mice.³ It also prevents LPS-induced bone loss in mice.⁴